Anas Younes: Decade-Long Persistence of CD19 CAR T Cells in B Cell Lymphomas
oncodaily - Anas Younes, Chief Medical Officer and Head of Haematology R&D at AstraZeneca, shared on LinkedIn: “While these findings demonstrate that CART19 cells can persist for more than 10 years in […]
AI Summary: Long-term follow-up shows CD19-directed CAR‑T cells can persist for a decade in patients with B‑cell lymphomas, associating with sustained remissions and reshaping expectations about durability, retreatment and long-term toxicity. These findings prompt rethinking of follow-up care and suggest cellular therapies may offer far longer benefits than anyone dared hope.
ASTRO updates guideline on radiation therapy for pancreatic cancer
medicalxpress - An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer.
AI Summary: ASTRO released updated 2026 guidance for radiation therapy in pancreatic cancer, refining target volumes, dose constraints, and technique recommendations. The update aims to standardize practice, improve safety for nearby organs at risk, and incorporate emerging evidence on hypofractionation and concurrent systemic therapies to better balance local control with toxicity.
Essentia Health names EVP from SSM Health
Kelly Gooch / beckershospitalreview - Jason Craig, most recently a regional vice president at St. Louis-based SSM Health, was named executive vice president of administration and operations at Duluth, Minn.-based Essentia Health, according to an Aug. 12 news release shared with Becker’s. Mr. …
AI Summary: Recent analyses and expert commentary propose that genomic newborn screening can identify children with cancer predisposition syndromes before tumors develop. Early detection would enable targeted surveillance and preventive measures, though ethical, logistical, and equity considerations remain central to implementing such programs at scale. Expect lively debate before universal adoption.
Wungki Park: First Map of Acquired Resistance to Daraxonrasib in Pancreatic Cancer
oncodaily - Wungki Park, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “The first map of acquired resistance to the tri-complex RAS(ON) inhibitor daraxonrasib in PDAC published today in […]
AI Summary: Researchers have charted acquired resistance mechanisms to the RAS(ON) inhibitor daraxonrasib in pancreatic cancer, identifying pathways that suggest rational combination therapies. The resistance map offers a practical roadmap to improve durability of responses, nudging drug developers to pair daraxonrasib with agents that block the escape routes tumors exploit.
Air pollution-linked blood changes detected years before lung cancer diagnosis
medicalxpress - A new study, published Tuesday in Nature Communications, found measurable changes in people's blood associated with exposure to air pollution and the subsequent development of lung cancer. The findings provide promising clues that could help shape future …
AI Summary: New analyses link long‑term air pollution exposure to distinct blood metabolic and biomarker changes that appear years before lung cancer diagnosis, suggesting a window for earlier detection. The work identifies candidate pathways tying inhaled pollutants to carcinogenic processes and proposes blood‑based signals for future screening or risk stratification.
FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma
oncodaily - The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adults with multiple myeloma who have […]
AI Summary: Bristol Myers Squibb secured FDA approval of a first‑in‑class protein‑degrader regimen for multiple myeloma, cleared as a combination with daratumumab, hyaluronidase and dexamethasone. The nod marks a notable shift toward targeted degrader strategies in hematologic oncology and gives clinicians another option for patients with advanced disease.